Advanced Renal Cell Carcinoma
Advertisement
Patients with accRCC were assigned to receive either a conventional continuation strategy or a drug-free interval strategy.
Plasma and urine free glycosaminoglycan profiles—or GAGomes—can potentially be used as metabolic biomarkers for mRCC.
Dr. McKay explains how radiation therapy and modalities fit into the treatment paradigm for RCC.
Dr. McKay summarizes the novel therapies or optimal sequencing patterns that are close to entering the mRCC treatment space.
Dr. McKay offers an overview of the second-line and later-line therapy options after progression for metastatic RCC.
Dr. McKay highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk mRCC.
Dr. Rana McKay details how advanced or mRCC is currently managed and how the treatment paradigm has evolved since 2018.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Researchers assessed TFS outcomes from HCRN GU16-260, investigating nivolumab and salvage nivolumab plus ipilimumab for aRCC.
Updated OS and efficacy results of second-line treatment in patients with mRCC treated in the BIONIKK trial were presented.
Latinx patients with mRCC demonstrated shorter PFS after nivolumab-plus-ipilimumab treatment at a tertiary care center.
A 24-month analysis highlighted OS, PFS, ORR, and best response to avelumab-plus-axitinib treatment in patients with aRCC.
Tian Zhang, MD, describes the current standard-of care treatment approach for metastatic RCC, including second-line therapy.
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.
Pembrolizumab/axitinib is a common first-line mRCC treatment, but its use in later lines of therapy has not been researched.
Researchers performed a cost-effectiveness analysis of sunitinib and 6 immunotherapy-TKI/immunotherapy drug combinations.
Three of the guideline authors offered additional information on cytoreductive nephrectomy and systemic treatment.
A study evaluated how accurately prospectively collected renal mass biopsy can identify DNA mutations in nephrectomy.
Gut bacteria play a role in the development of sarcopenia in metastatic renal cell carcinoma.
Following AUA guidelines may increase survival in kidney cancer.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726